Arena Pharma (ARNA) Belviq Numbers Lowered at Needham & Company
Tweet Send to a Friend
Needham & Company analyst Alan Carr reiterated Hold rating and lowered estimates on Arena Pharma (NASDAQ: ARNA) ahead of Q1 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE